A review of the successes and failures of the past indicates that the current products on the market or in development that attempt to utilize the immune system to rid the body of cancer have the following draw backs:
1) They are given to patients after the patient has received
chemotherapy, radiation or surgery. This is most often too late!!!
At that point the patient's immune system is so damaged from the
patient's cancer and the cancer therapy that it can no longer mount
an effective anti-tumor immune response.
2) They are targeted to a specific antigen on a tumor and attack that
tumor only in one way. There are many antigens that need to be
attacked to overcome the very complex tumor defense mechanisms and
the constant mutation of the tumor antigens cannot be addressed with
a 'one key fits all' approach.
3) They act like specific parts of our immune system, when in reality
we need a more complete immune approach (the whole army vs.
specialized soldiers only).
Cancer is a very complex disease and requires a comprehensive immune system approach. Our Multikine is designed to address the shortfalls outlined above and provide a comprehensive anti-tumor immune response that most closely resembles the workings of the natural immune system. It is comprehensive in the sense that it works on multiple fronts in the battle against cancer, and it is toxic only to cancer cells.
Multikine represents a new class of immunotherapy drugs, Immune SIMULATORS, since it simulates a healthy immune response. It works 1) because it is given prior to the first cancer treatment, before the immune system is weakened by standard cancer therapies, and 2) because it attacks the tumor on multiple fronts (multi-targeted), not only one front.
Multikine is multi-targeted because:
1) It acts on multiple targe
|SOURCE CEL-SCI Corporation|
Copyright©2007 PR Newswire.
All rights reserved